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Tae Ryong Lee1, Kwangmi Kim3, Ai-Young Lee4 and Minsoo Noh2
Skin diseases can be characterized by their predominant CD4-positive T-helper (Th) cell profiles. Chronic
dermatological conditions often give rise to abnormal skin pigmentation. To understand the role of Th cells in
pigmentation, the effects of the major Th cell cytokines, IFNg, IL-4, and IL-17A, on melanogenesis were evaluated
using cultured normal human melanocytes (NHMs) instead of relying on transformed melanoma cell lines. IL-4
directly inhibited melanogenesis in NHMs and downregulated both transcription and translation of melanogen-
esis-associated genes, such as microphthalmia-associated transcription factor (MITF) and dopachrome tautomer-
ase. Despite the lack of a direct inhibition of melanin pigment synthesis, IFNg and IL-17A increased the synthesis
of an antimelanogenic cytokine IL-6 in NHMs. IFNg activated signal transducers and activators of transcription 1
(STAT1) and STAT3 phosphorylation in NHMs, and IL-4 increased the STAT3 and STAT6 phosphorylation. The
differential phosphorylation profile of STAT proteins between IFNg and IL-4 may explain the difference in their
effect on melanogenesis in NHMs. The IL-4-induced downregulation of melanogenesis was inhibited by treating
NHMs with a JAK2 inhibitor AG490 or STAT6 siRNA. In conclusion, the involvement of the IL-4-induced JAK2–
STAT6 signaling and the IFNg- or IL-17A-dependent antimelanogenic IL-6 production should be considered as one
of the mechanisms explaining the association with hypopigmention in skin diseases.
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INTRODUCTION
Epidermal melanocytes synthesize melanin pigments from
tyrosine and accumulate melanin in specialized cellular
organelles called melanosomes, which are transported from
melanocytes to adjacent keratinocytes (Costin and Hearing,
2007; Lin and Fisher, 2007). Cytokines and related inflam-
matory mediators directly or indirectly regulate proliferation,
differentiation, and the rate of melanogenesis in human
epidermal melanocytes (Imokawa, 2004; Slominski et al.,
2004; Hirobe, 2005). Environmental factors, such as UV
irradiation, and dermatological conditions, such as atopic
dermatitis, psoriasis, and other autoimmune disorders, can
affect cytokine levels in human skin tissues (Slominski et al.,
2004; Dessinioti et al., 2009).
In contrast to the effects of the acute-phase inflammatory
cytokines, such as IL-1a, IL-6, and tumor necrosis factor-a, on
melanogenesis (Swope et al., 1991), it is relatively unknown
how cytokines mediating the chronic inflammatory reactions
regulate human melanogenesis. In chronic skin diseases, CD4-
positive T-helper (Th) cells are involved in the inflammatory
response of lesional skin (Howell et al., 2007; Zaba et al.,
2009). Proinflammatory Th cells are classified into three major
subtypes, Th1, Th2, and Th17, based on their cytokine
secretion profile (Wilson et al., 2009). Each skin disease is
characterized by its predominant Th cell subtype. For
example, IFNg–producing Th1 cells in the human epidermis
have a role in the pathogenesis of psoriasis (Zaba et al., 2009).
Th2 cytokines, such as IL-4, are predominantly detected in
lesional skin associated with atopic dermatitis (Howell et al.,
2007). Roles of IL-17A in chronic psoriatic skin lesions or in
vitiligo skin lesions have been recently reported (Basak et al.,
2009; Zaba et al., 2009; Bassiouny and Shaker, 2011). With
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regard to melanogenesis, IFNg, a Th1 cytokine, was deter-
mined to be associated with the downregulation of melano-
somal antigens, such as tyrosinase, tyrosinase-related protein
(TRP)-1, dopachrome tautomerase (DCT), gp100/PMEL17
(melanocyte protein 17; PMEL17), and MART1 (melanoma
antigen recognized by T cells 1) in melanoma cells (Garbe
et al., 1990; Le Poole et al., 2002). Compared with melanoma
cells, the effects of IFNg on melanogenesis in normal human
melanocytes (NHMs) are not fully elucidated. Similar to IFNg,
it is still unclear whether IL-4 and IL-17A can directly affect
the mitogenic and melanogenic activities of NHMs.
Th cell cytokines trigger and activate cellular signal trans-
duction through the JAK signal transducers and activators of
the transcription (STAT) pathway and/or other pathways, such
as the mitogen-activated protein kinase pathway (Englaro
et al., 1998; Murray, 2007; Yoshimura et al., 2007). The
mitogen-activated protein kinase pathway has been exten-
sively studied using B16 melanoma cells (Englaro et al., 1998;
Khaled et al., 2003; Bellei et al., 2010). The regulation of
melanogenesis by the JAK–STAT pathway has been poorly
explored in NHMs compared with studies on the association
of the mitogen-activated protein kinase pathway in melano-
genesis. Because STAT3 is constitutively activated in various
melanomas (Yu and Jove, 2004), the JAK–STAT pathway may
affect the proliferation and melanogenesis of NHMs. How-
ever, it is unclear how proinflammatory Th cell cytokines that
are increased in human skin diseases affect the JAK–STAT
pathway in terms of the regulation of melanocyte function, such
as melanogenesis. In this study, to evaluate the effects of Th
cytokines on cutaneous pigmentation in human skin diseases,
the melanogenesis of NHMs was evaluated after treating primary
NHM cultures with IFNg, IL-4, or IL-17A, which are representa-
tive Th1, Th2, and Th17 cytokines, respectively (Figure 1a).
RESULTS
IL-4 decreased melanin synthesis and the gene transcription of
melanogenesis-associated proteins in NHMs
To evaluate whether Th cytokines have an effect on melano-
genesis in NHMs, we first performed cytokine viability assays
to determine the noncytotoxic concentrations (Figure 1b–d).
We treated NHMs with 200 IU IFNg, 25 ng ml1 IL-4, and
50 ng ml1 IL-17A and harvested the cells at 72 hours after
cytokine treatment for the quantification of the intracellular
melanin levels (Figure 1e). IL-4 decreased the melanin content
by 37% in NHMs compared with the vehicle-treated control
(Figure 1e, Po0.05, n¼3). In contrast, there were no
significant changes in melanin accumulation in NHMs treated
with either IFNg or IL-17A. We also evaluated the gene
transcriptional profiles of the melanogenesis-associated pro-
teins, such as microphthalmia-associated transcription factor
(MITF), tyrosinase, TRP-1, DCT, MART1, and gp100/PMEL17
in NHMs in response to treatment with Th cytokines. The
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Figure 1. Effects of IFNc, IL-4, and IL-17A on melanogenesis in normal human melanocytes (NHMs). (a) Cell viability was evaluated for (b) IFNg, (c) IL-4,
and (d) IL-17A using 4-3-[4-iodophenyl]-2-4(4-nitrophenyl)-2H-5-tetrazolio-1,3-benzene disulfonate. NHMs were stimulated with 200 IU IFNg, 25 ng ml1
IL-4, and 50 ng ml1 IL-17A for 72 hours before the spectrophotometric measurement of melanin. The melanin contents were normalized on the basis of
protein concentrations (e). Total RNA was extracted from NHMs at 24 hours after cytokine treatments, and quantitative real-time reverse transcriptional PCR
(qRT–PCR) was performed for (f) microphthalmia-associated transcription factor (MITF), (g) tyrosinase, (h) tyrosinase-related protein 1 (TRP-1), (i) dopachrome
tautomerase (DCT), (j) melanoma antigen recognized by T cells 1 (MART1), and (k) melanocyte protein 17 (gp100/PMEL17). CON represents a sample
from unstimulated NHM control. The values shown represent the mean±SD of three independent NHM cultures (n¼3). *Pp0.05 and **Pp0.01.
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quantitative real-time reverse transcriptional PCR (qRT–PCR)
results showed that IL-4 treatment significantly downregulated
the mRNA levels of MITF, tyrosinase, DCT, MART1, and
gp100/PMEL17 (Figure 1). IL-4 did not alter TRP-1 gene
transcription in NHMs at 24 hours after cytokine treatment
(Figure 1h). Despite the fact that there was no effect on
melanin synthesis in NHM cultures, IFNg significantly down-
regulated DCT gene transcription (Figure 1i).
IL-4 decreased protein expression of MITF, TRP-1, DCT1, and
gp100/PMEL17 in NHMs
To confirm the effect of IL-4 on melanogenesis, protein levels
were measured in NHMs treated with IL-4 for 72 hours
(Figure 2). Although the mRNA levels of tyrosinase and TRP-
1 were variable at 24 hours after IL-4 treatment by different
NHM batches, the decrease of the gene expression was
statistically significant by 72 hours of treatment (Figure 2a–f).
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Figure 2. Effects of IL-4 on melanogenesis-associated protein expression in normal human melanocytes (NHMs). For measuring mRNA levels, NHMs were
cultured and harvested at both 24 and 72 hours after the IL-4 treatment and quantitative real-time reverse transcriptional PCR (qRT–PCR) was performed (a–e). In
parallel NHM cultures, cells were harvested for immunoblotting analysis at 72 hours after the IL-4 treatment and cell pellets in tubes were photographed. Protein
levels were measured for microphthalmia-associated transcription factor (MITF), tyrosinase, tyrosinase-related protein 1 (TRP-1), dopachrome tautomerase (DCT),
melanoma antigen recognized by T cells 1 (MART1), and melanocyte protein 17 (gp100/PMEL17) (f). For evaluating tyrosinase protein expression in the long-term
culture, NHMs were cultured for 6 days and harvested (g). CON represents a sample from unstimulated NHM control (h). The mean±SD was calculated with
three independent NHM cultures. *Pp0.05, **Pp0.01. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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In western blot analysis, IL-4 significantly decreased MITF,
TRP-1, DCT, MART1, and gp100/PMEL17 as it effects on gene
transcription (Figure 2g). Despite the downregulation of
tyrosinase gene transcription, the changes in tyrosinase
protein expression were not statistically significant in the
western blot analysis in three independent experiments.
When NHMs were cultured in the presence of IL-4 for 6
days (Figure 2h), in spite of the slight decrease in tyrosi-
nase protein expression (15.7% at the day 6, Figure 2h), its
change was statistically insignificant in four independent
experiments. The difference between mRNA and protein
changes for tyrosinase may be explained by the longer
intracellular half-life of tyrosinase protein compared
with other melanogenesis-associated proteins (Slominski
et al., 2004).
STAT1, STAT3, and STAT6 were activated after treating NHMs
with IFNc and IL-4
Although JAK–STAT is one of the essential pathways to
mediate Th cytokine signaling, its role in melanogenesis has
been poorly explored in NHMs. To characterize the activation
of the JAK–STAT signaling pathways in NHMs, we evaluated
the cellular phosphorylation levels of STAT1, STAT3, and
STAT6 in NHMs at 24 hours after treatments with IFNg, IL-4,
or IL-17A. We determined that STAT1 phosphorylation was
upregulated in NHMs in response to IFNg (Figure 3). IFNg and
IL-4 increased STAT3 phosphorylation in NHMs (Figure 3).
STAT6 phosphorylation was increased in NHMs treated with
IL-4 (Figure 3). No phosphorylation of STAT2, STAT4, or
STAT5 was detected following treatments of IFNg and IL-4
(data not shown). IL-17A did not alter the level of STAT
phosphorylation in NHMs (Figure 3).
IFNc and IL-17A increased IL-6 production in NHMs
NHMs can produce various cytokines, such as IL-1b, IL-6, and
GM-CSF, which can regulate the proliferation and melano-
genesis in an autocrine manner (Imokawa, 2004; Slominski
et al., 2004). Interestingly, IL-17A increases IL-6 production in
various somatic tissue cells (Noh et al., 2010). To determine
whether Th cytokines regulate melanogenesis in an autocrine
manner, we measured mRNA levels of IL-1b, IL-6, and
GM-CSF in NHMs treated with Th cell cytokines (Figure 4).
Treatment with IFNg, IL-4, or IL-17A had no effect on the
mRNA expression levels of IL-1b and GM-CSF (Figure 4a
and b). IL-6 gene transcription in NHMs treated with IFNg
or IL-17A was significantly higher compared with the vehicle-
treated control (Figure 4c). In addition, NHMs secreted IL-6
proteins in culture supernatants in response to IFNg or
IL-17A (Figure 4d). There was no effect of IL-4 on IL-6
production in NHMs (Figure 4). Although IFNg and IL-17A
stimulated the production of antimelanogenic cytokine IL-6
(Figure 4), the IL-6 concentration in the NHM culture may
not be sufficient to activate antimelanogenic cellular
mechanism (Figure 1).
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Figure 3. Phosphorylation profile of signal transducers and activators of
transcription (STATs) in normal human melanocytes (NHMs) in response to
IFNc, IL-4, and IL-17A. NHMs were stimulated with 200 IU IFNg, 25 ng ml1
IL-4, and 50 ng ml1 IL-17A for 24 hours. Whole-cell lysates were subjected to
SDS-PAGE and analyzed by immunoblotting with antiphospho-STAT1,
antiphospho-STAT3, antiphospho-STAT6, anti-STAT1, anti-STAT3, or anti-
STAT6 antibody. CON represents a sample prepared from unstimulated NHM
control. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
3 IL-1β
2
R
el
at
iv
e 
m
R
N
A
R
el
at
iv
e 
m
R
N
A
1
0
16 250
200
150
100
50
0
IL-6
**
**
*
**
IL
-6
 (p
g m
l–1
)
12
8
4
0
2 GM-CSF
R
el
at
iv
e 
m
R
N
A
1
0
CO
N
IF
N
γ
IL
-4
IL
-4
IL
-1
7A
CO
N
IF
N
γ
IL
-4
IL
-1
7A
CO
N
IF
N
γ
IL
-4
IL
-1
7A
CO
N
IF
N
γ
IL
-1
7A
Figure 4. Effects of IFNc, IL-4, and IL-17A on IL-1b, GM-CSF, and IL-6
expression in normal human melanocytes (NHMs). NHMs were stimulated
with 200 IU IFNg, 25 ng ml1 IL-4, and 50 ng ml 1 IL-17 A for 24 hours. Total
RNA was extracted, and quantitative real-time reverse transcriptional PCR
(qRT–PCR) was performed for (a) IL-1b, (b) GM-SCF, and (c) IL-6. (d) An ELISA
was performed with culture supernatants harvested 24 hours after cytokine
treatments to determine IL-6 expression. Values represent the mean±SD of
results from three independent NHM cultures (n¼3). *Pp0.05, **Pp0.01.
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JAK2 inhibition antagonized IL-4-dependent downregulation of
melanogenesis-associated protein transcription in NHMs
IL-4 receptor signaling requires the activation of JAK1, JAK2,
and/or JAK3, followed by the phosphorylation of STAT
proteins (Schindler et al., 2007). To elucidate whether there
is a direct association of IL-4 with the inhibition of melano-
genesis in NHMs, we treated NHMs with piceatannol,
AG490, and WHI-P131 to inhibit JAK1, JAK2, and JAK3,
respectively (Figure 5). In the presence of IL-4, only AG490, a
JAK2 inhibitor, significantly inhibited the IL-4-induced tran-
scriptional downregulation of MITF, tyrosinase, MART1, and
gp100/PMEL17, whereas piceatannol or WHI-P131 did not
have this effect (Figure 5). Although the IL-4-induced decrease
in DCT gene transcription was not affected by AG490, this
result suggests that JAK2 has a role in the effect of IL-4 on the
melanogenesis of NHMs.
Interestingly, the mRNA levels of tyrosinase in NHMs
treated with AG490 or WHI-P131 were even higher than
controls not treated with IL-4 (Figure 5b). In western blot
analysis, tyrosinase expression was observed to be upregulated
in NHMs treated with AG490 and WHI-P131, which is con-
sistent with the detected transcriptional changes (Figure 5g).
However, when the melanin content was measured in NHM
cultures, the JAK2 inhibitor AG490 increased melanogenesis
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Figure 5. Association of JAK2 inhibition with the IL-4-dependent downregulation of melanogenesis in normal human melanocytes (NHMs). For quantitative real-
time reverse transcriptional PCR (qRT–PCR) analysis, NHMs were incubated with or without 10mM piceatannol for JAK1 inhibition (Jak1), 25mM AG490 for JAK2
(Jak2), and 25mM WHI-P131 for JAK3 (Jak3) with or without 25 ng ml 1 IL-4 for 24 hours. The mRNA levels represent the mean expression±SD of values relative
to human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression (three independent NHM cultures, n¼ 3) (a–f). For western blot analysis of tyrosinase
(g) and for measurement of melanin content (h), NHMs were treated with JAK inhibitors for 72 hours. *Pp0.05, **Pp0.01. DCT, dopachrome tautomerase;
MART1, melanoma antigen recognized by T cells 1; MITF, microphthalmia-associated transcription factor; TRP-1, tyrosinase-related protein 1.
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by 39%, whereas piceatannol and WHI-P131 had no
significant effect (Figure 5h). Therefore, WHI-P131 may have
an effect on other factors in NHMs that neutralize the
upregulation of tyrosinase expression. In conclusion, JAK2 is
predominantly associated with melanogenesis in NHMs.
STAT6 siRNA transfection inhibited the IL-4-dependent
downregulation of melanogenesis-associated protein
transcription in NHMs
Although IFNg and IL-4 increased STAT3 phosphorylation in
NHMs (Figure 3), only IL-4 significantly affected melanin
synthesis (Figure 1). Because IL-4 specifically increased STAT6
phosphorylation (Figure 3), we evaluated whether STAT6
phosphorylation was directly associated with the IL-4-depen-
dent downregulation of melanogenesis. After transfection of
NHMs with STAT6 siRNA, we confirmed the downregulation
of STAT6 mRNA levels by qRT–PCR (Figure 6a). STAT6 siRNA
treatment did not alter the expression of the melanogenesis-
associated proteins, such as MITF, tyrosinase, DCT, MART1,
or gp100/PMEL17 (Figure 6a–g). When we applied IL-4 to
NHM cultures, STAT6 siRNA treatment inhibited the IL-4-
dependent downregulation of MITF, tyrosinase, TRP-1, DCT,
and gp100/PMEL17 (Figure 6a–h); however, no significant
difference in MART1 gene transcription was observed in
NHMs following STAT6 siRNA treatment (Figure 6g). In
western blot analysis, we confirmed that STAT6 siRNA
attenuated the effect of IL-4 on TRP-1 and DCT (Figure 6h).
In contrast, tyrosinase protein expression was insensitive to
IL-4 as well (Figure 6h).
DISCUSSION
Acute and chronic inflammation due to various dermatologi-
cal conditions may result in either hypopigmentation or
hyperpigmentation, depending on the interactions between
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Figure 6. Effects of signal transducers and activators of transcription (STAT)6 small interfering RNA (siRNA) treatment on IL-4-dependent downregulation of
melanogenesis in normal human melanocytes (NHMs). For downregulation of STAT6, NHMs were transfected with 50 nM of STAT6 siRNA or negative control
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environmental and genetic factors (Slominski et al., 2004). In
this study, we found that IL-4, a representative cytokine for
Th2, directly inhibited melanin pigment synthesis in NHMs
through the JAK2–STAT6 signaling pathway. The pathophy-
siology of atopic dermatitis is related to Th2 cell cytokines,
such as IL-4 and IL-13 (Boguniewicz and Leung, 2011).
In atopic dermatitis, the pathological mechanism associated
with abnormal skin pigmentation in lesional areas is still
unclear. It was observed that patients with atopic dermatitis
tend to present fewer melanocytic nevi compared with healthy
control groups, which suggests inhibition of the mitogenic
and melanogenic activities of human melanocytes (Broberg
and Augustsson, 2000; Synnerstad et al., 2004). In this study,
we demonstrated that the IL-4-induced downregulation of
melanogenesis was inhibited by treating NHMs with the JAK2
inhibitor, AG490, and by STAT6 siRNA knockdown. Although
IL-4 can contribute to decreasing the number of melanocytic
nevi in atopic dermatitis (Broberg and Augustsson, 2000;
Synnerstad et al., 2004), it is still possible that other proinflam-
matory cytokines mediate the development of atopic lesional
skin, such as IL-1a, IL-17A, and tumor necrosis factor-a, and
may also be involved in abnormal skin pigmentation
associated with atopic dermatitis (Boguniewicz and Leung,
2011). Therefore, combinatorial effects of these cytokines on
melanogenesis in NHMs should be considered when studying
abnormal skin pigmentation related to atopic dermatitis. In
chronic inflammation, IL-4 is also produced by CD8-positive
cytotoxic T cells, basophils, eosinophils, and activated mast
cells, which have roles in the pathogenesis of atopic dermatitis
and other skin diseases (Barata et al., 1998; Gessner et al.,
2005). In skin tissue, IL-4 affects melanogenesis in epidermal
melanocytes and various functions of epidermal keratinocytes,
dermal fibroblasts, dendritic cells, and other proinflammatory
infiltrating lymphocytes, all of which directly or indirectly
regulate melanocyte function as neighboring cells (Slominski
et al., 2004). Therefore, to understand the different phenotypes
of abnormal skin pigmentation in various types of atopic
dermatitis, further studies should be directed toward eluci-
dating how interactions between IL-4 and other proinflam-
matory cytokines affect melanogenesis in NHMs in the context
of the autocrine or paracrine networks between melanocytes
and their neighboring cells in human skin.
Although IFNg and IL-17A had no direct effect on melano-
genesis, they increased IL-6 production in NHMs. Recently, it
was reported that melanogenesis of NHMs was inhibited by
IL-6 produced in human keratinocytes through paracrine
regulation (Imokawa, 2004; Choi et al., 2005). Because
IFNg and IL-17A increased IL-6 production in epidermal
keratinocytes (Fujisawa et al., 1997; Peric et al., 2008), it
may be possible that IFNg and IL-17A can indirectly regulate
skin pigmentation through the upregulation of IL-6 in both
melanocytes and keratinocytes; further studies are necessary
to investigate this hypothesis. In addition, IFNg, a Th1
cytokine, significantly decreased the mRNA levels of DCT in
NHMs (Figure 1i). It suggests that IFNg can change the quality
of melanin pigments by modulating the activity of DCT,
an enzyme that catalyzes the isomerization of dopachrome
to 5,6-dihydroxyindole-2-carboxylic acid, a precursor of
eumelanins (Slominski et al., 2004). Mutations in DCT have
been determined to cause an increase in pheomelanin and a
decrease in eumelanin produced by human melanocytes in
culture (Costin et al., 2005). Therefore, the IFNg-dependent
downregulation of DCT gene transcription may influence the
relative eumelanin/pheomelanin content in NHMs. Therefore,
these results suggest that Th cells may contribute to postin-
flammatory hyperpigmentation or hypopigmentation in skin
lesions associated with various dermatological conditions
through either direct or indirect pathways.
In terms of JAK–STAT signaling, IFNg significantly increased
both STAT1 and STAT3 phosphorylation (Figure 3). IL-4 also
increased STAT3 phosphorylation in NHMs (Figure 3).
Although IFNg and IL-4 activated STAT3 phosphorylation,
IL-4 decreased intracellular melanin synthesis in NHMs and
IFNg did not. Therefore, the role of the IL-4-induced STAT3
phosphorylation in melanogenesis may be limited compared
with STAT6 phosphorylation. Interestingly, STAT1 and STAT3
often have mutually antagonistic roles in the regulation of
cellular proliferation and differentiation (Shen et al., 2001;
Qing and Stark, 2004). Therefore, we cannot exclude the
possibility that STAT3 signaling contributes to the down-
regulation of melanin synthesis in NHMs and that IFNg-
dependent STAT3 activation may be antagonized by STAT1
activation. Further studies should be directed toward address-
ing the intracellular interaction between the STAT1 and STAT3
signaling pathways in response to IFNg in terms of the
regulation of melanogenesis in NHMs. Taken together, the
differential phosphorylation profiles of STAT1, STAT3, and
STAT6 in response to IFNg and IL-4 treatment may explain the
difference in their effects on melanin synthesis and expression
of melanogenesis-associated genes.
Constitutive STAT3 activation is linked to malignant mela-
noma (Niu et al., 2002; Yu and Jove, 2004; Xie et al., 2006).
Considering that chronic inflammation has a role in cancer
development (Coussens and Werb, 2002), chronic activation
of STAT3 in NHMs by IFNg and IL-4 in various dermatological
conditions may be linked to their melanoma progression.
Although abnormal STAT3 signaling is evident in human
melanomas, the development of melanoma in normal mela-
nocytes in terms of the STAT signaling pathways remains
poorly understood. Interestingly, it was reported that a positive
correlation existed between the number of melanocytic nevi
and the risk of melanoma (Bauer and Garbe, 2003). Despite
the presence of chronic inflammation and cytokines that may
constitutively activate STAT3 phosphorylation in patients with
atopic dermatitis, it is unclear whether they represent a high-
risk group for melanoma development. Interestingly, IL-4
significantly decreased MITF gene transcription in NHMs
(Figure 2). MITF levels are generally upregulated in various
melanomas, and this transcription factor can regulate the
proliferation and development of epidermal melanocytes
(Vachtenheim and Borovansky´, 2010). Consequently, the
IL-4-induced downregulation of MITF may be related to the
decreased number of melanocytic nevi in atopic dermatitis.
Therefore, revealing the link between chronic STAT3
activation by IL-4 and melanoma risk in future research will
be necessary. To understand the progression of melanoma in
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human melanocytes in terms of JAK–STAT signaling, various
positive and/or negative signaling factors in this pathway
should be considered (Yu and Jove, 2004). In the JAK–STAT
signaling pathway, the SOCS (suppressors of cytokine signal-
ing) and PIAS (protein inhibitors of activated stats) proteins
regulate cytokine signaling. It was recently reported that the
functions of MITF can be regulated by the interaction between
STAT3 and PIAS3 (Vachtenheim and Borovansky´, 2010),
suggesting that melanocyte functions can be modulated by
overall interactions among JAKs, STATs, and their functional
regulators, such as SOCSs and PIASs. Therefore, to understand
abnormal skin pigmentation associated with various der-
matological conditions, further studies will be required to
reveal the roles of SOCSs and PIASs in Th cell cytokine–
dependent melanogenic regulation in NHMs.
In this study, we used NHMs whose ethnic background is
related to native Chinese, Japanese, and Korean. In our experi-
ence, the effects of T-helper cell cytokines on NHMs are
variable among melanocyte batches with different ethnic
backgrounds. For example, 200 IU of IFNg, the concentration
we used in this study, affected the viability of melanocytes
with African-American origin, whereas Caucasian-origin mel-
anocytes were viable up to 500 IU (data not shown). There-
fore, it will be interesting to address the genetic variability
about the responses of NHMs to Th cytokines in the future.
In conclusion, to understand the hypopigmenation that
abnormally appears in lesional skin associated with various
dermatological conditions, such as atopic dermatitis and
psoriasis, the involvement of the IL-4/JAK2/STAT6 signaling
pathway or IFNg- or IL-17A-dependent antimelanogenic IL-6
production should be considered as one of the key mechan-
isms explaining the association between these conditions and
abnormal skin pigmentation.
MATERIALS AND METHODS
Primary melanocyte culture and cytokine treatment and
quantification of melanin synthesis
NHMs from the neonatal foreskin of moderately pigmented donors
were purchased from Cascade Biologics (#C-102–5C; Portland, OR)
and cultured in Medium 254 (#M-254–500; Cascade Biologics)
supplemented with human melanocyte growth supplement (HMGS)
(Cascade Biologics). NHMs were confluently grown in Medium 254
and HMGS. At 48 hours before cytokine treatment to NHMs, culture
media were exchanged with Medium 254 and phorbol 12-myristate
13-acetate (PMA)-free HMGS-2 (Cascade Biologics). The cells were
treated with 200 IU IFNg, 25 ng ml 1 IL-4, or 50 ng ml 1 IL-17A
(R&D Systems, Minneapolis, MN) for experiments. Pretreatment with
10mM piceatannol for JAK1 inhibition, 25mM AG490 for JAK2, and
25mM WHI-P131 for JAK3 (Calbiochem, Darmstadt, Germany) was
carried out for 20 minutes, and the cells were cotreated with
25 ng ml 1 of IL-4. Three independent cell cultures were tested.
Quantification of melanin synthesis and cell cytotoxicity assays in
NHMs was performed as described (Choi et al., 2005). Briefly, the
cell lysates were prepared by sonicating NHMs in 0.1 M Tris-HCl (pH
7.2) buffer containing 1% Nonidet P-40, 0.01% SDS, and a protease
inhibitor cocktail (Roche Molecular Biochemical, Indianapolis, IN).
Melanin was separated from cell lysates by centrifugation at
12,000 r.p.m. for 15 minutes at 4 1C before being dissolved in 1 N
NaOH. The melanin content was assayed in a spectrophotometer at
490 nm, and the relative quantity was normalized with protein con-
centration of each sample. All statistical analyses were performed
with the MINITAB software (Minitab State College, PA).
Quantitative real-time reverse transcriptional PCR (qRT–PCR)
Quantitative measurements of melanogenesis markers and other
genes were recorded as previously described (Noh et al., 2010).
The cDNA samples were analyzed to detect the expression of
tyrosinase (Applied Biosystems, Foster City, CA, Hs01099965_m1),
TRP-1 (Hs00167051_m1), DCT (Hs01095856_m1), MART1
(Hs00194133_m1), gp100/PMEL17 (Hs00173854_m1), IL-1b
(Hs01555410_m1), IL-6 (Hs00985639_m1), GM-CSF (Hs00929873_
m1), STAT6 (Hs00598625_m1), and MITF (Hs01117294_m1). To
normalize the mRNA expression levels, the relative expression
of glyceraldehyde-3-phosphate dehydrogenase (4333764F) was
analyzed. Quantification of relative expression levels was performed
using equations from a mathematical model developed by Pfaffl
(2001).
Western blot analysis
Protein levels were determined as described (Choi et al., 2005) with
antiphospho STAT1 antibody (#9171, Cell Signaling Technology (CST),
Beverly, MA), anti-STAT1 antibody (#9172, CST), antiphospho STAT2
antibody (#4441, CST), anti-STAT2 antibody (#4594, CST), antiphospho
STAT3 antibody (#9145, CST), anti-STAT3 antibody (#9132, CST),
antiphospho STAT6 antibody (#9361, CST), anti-STAT6 antibody
(#9362, CST), and anti-glyceraldehyde-3-phosphate dehydrogenase
(Santa Cruz Biotechnology, sc25778). Antibodies to detect MITF
(Neomarkers, Fremont, CA), tyrosinase (Upstate biotechnology, Lake
Placid, NY), TRP-1 (sc25543, Santa Cruz Biotechnology, Santa Cruz,
CA), DCT (sc74439, Santa Cruz Biotechnology), MART1
(Neomarkers), and gp100/PMEL17 (Abcam, Cambridge, MA) were
used as described (Choi et al., 2005).
Small interfering RNA transfection
NHMs cultured in 60-mm dishes were transfected with siRNA
SMARTpool STAT6 (#M-006690, Dharmacon, Lafayette, CO) and a
siGENOME non-targeting siRNA Pool #2 (D-001206-14, Dharmacon)
using Lipofectamine RNAi MAX (Invitrogen, Carlsbad, CA) and 50 nM
siRNA according to the manufacturer’s instructions.
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